How Does Liminal BioSciences Inc (LMNL) Stock Rank on Wall Street Thursday?

Thursday, June 30, 2022 12:47 PM | InvestorsObserver Analysts

Mentioned in this article

InvestorsObserver is giving Liminal BioSciences Inc (LMNL) an Analyst Rating Rank of 5, meaning LMNL is ranked higher by analysts than 5% of stocks. The average price target for LMNL is $2 and analyst’s rate the stock as a Hold.

Wall Street analysts are rating LMNL a Hold today. Find out what this means to you and get the rest of the rankings on LMNL!
See Full LMNL Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Liminal BioSciences Inc Stock Today?

Liminal BioSciences Inc (LMNL) stock is higher by 20% while the S&P 500 has fallen -0.31% as of 12:47 PM on Thursday, Jun 30. LMNL has risen $0.09 from the previous closing price of $0.45 on volume of 249,091 shares. Over the past year the S&P 500 is down -11.42% while LMNL has fallen -86.12%. LMNL earned $0.61 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 0.89. Click Here to get the full Stock Report for Liminal BioSciences Inc stock.

Share this article:

Related Articles